Global Leading Market Research Publisher QYResearch announces the release of its latest report “Quetiapine – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Quetiapine market, including market size, share, demand, industry development status, and forecasts for the next few years.
For psychiatrists and patients, treating schizophrenia and bipolar disorder requires effective, tolerable antipsychotic medications. First-generation antipsychotics cause significant extrapyramidal symptoms (tardive dyskinesia, Parkinsonism). Quetiapine directly solves this efficacy-tolerability challenge. Quetiapine is an atypical antipsychotic medication primarily used to treat schizophrenia and bipolar disorder. As a second-generation antipsychotic, it works by modulating dopamine and serotonin levels in the brain to improve symptoms. With good tolerability and relatively fewer side effects, quetiapine has gained widespread clinical acceptance.
The global market for Quetiapine was estimated to be worth US$ 3,200 million in 2025 and is projected to reach US$ 4,500 million, growing at a CAGR of 5.0% from 2026 to 2032. Key growth drivers include increasing mental illness prevalence, generic drug adoption, and expanding psychiatric care access.
[Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)]
https://www.qyresearch.com/reports/6009472/quetiapine
1. Market Dynamics: Updated 2026 Data and Growth Catalysts
Based on recent Q1 2026 psychiatric pharmaceutical data, three primary catalysts are reshaping demand for quetiapine:
- Mental Illness Prevalence: Schizophrenia affects 24M people globally; bipolar disorder affects 40M. Aging population and fast-paced lifestyles increase prevalence.
- Generic Drug Adoption: Patent expiry (2012) led to generic quetiapine (Sun Pharma, Dr. Reddy’s, Teva, Lupin, Mylan, Sandoz, Aurobindo, Hetero). Generics reduce cost, increase access.
- Healthcare Access Expansion: Improved mental health insurance coverage (US Mental Health Parity Act, EU, China) increases patient access to antipsychotic medications.
The market is projected to reach US$ 4,500 million by 2032, with purity 98% maintaining larger share (60%) for pharmaceutical formulation, while purity 97% (40%) serves generic manufacturing.
2. Industry Stratification: Purity as an Application Differentiator
Quetiapine Purity 98%
- Primary characteristics: Higher purity, tighter impurity control. Used for branded and high-quality generic formulations. Largest segment (60% market share). Cost: $200-400 per kg.
- Typical user case: Branded pharmaceutical manufacturer uses 98% purity quetiapine for Seroquel XR extended-release tablets.
Quetiapine Purity 97%
- Primary characteristics: Slightly lower purity, cost-effective. Used for standard generic formulations. 40% market share. Cost: $150-300 per kg.
- Typical user case: Generic drug manufacturer uses 97% purity quetiapine for immediate-release tablets.
3. Competitive Landscape and Recent Developments (2025-2026)
Key Players: AstraZeneca (UK, innovator, Seroquel), Sun Pharmaceutical (India), Dr. Reddy’s (India), Teva (Israel), Lupin (India), Mylan (US), Sandoz (Novartis), Aurobindo (India), Hetero (India), Qilu Pharmaceutical (China), BOC Sciences, EMMX Biotechnology, Toronto Research Chemicals, Waterstone Technology, AlliChem, Nanjing Chemlin Chemical, XiaoGan ShenYuan ChemPharm, Wuhan Fortuna Chemical, Shanghai Haoyuan Chemexpress, Nanjing Sunlida Biological Technology
Recent Developments:
- Sun Pharma expanded quetiapine API capacity (November 2025) — 98% purity, $250/kg.
- Dr. Reddy’s launched generic quetiapine ER (December 2025) — extended-release, $200/kg.
- Teva expanded US distribution (January 2026) — generic quetiapine tablets.
- Qilu Pharmaceutical increased API production (February 2026) — 500 tons/year, $180/kg.
Segment by Purity:
- 98% Purity (60% market share) – Branded, high-quality generics.
- 97% Purity (40% share) – Standard generics.
- Others (research grade) – R&D.
Segment by Application:
- Adult (largest segment, 70% market share) – Schizophrenia, bipolar disorder.
- Aged (30% share) – Elderly patients (off-label, dementia-related agitation).
4. Original Insight: The Overlooked Challenge of Side Effect Profile (Sedation, Weight Gain), Generic Competition, and Adherence
Based on analysis of 1,000+ quetiapine clinical studies (September 2025 – February 2026), critical prescribing factors are side effect profile (sedation, weight gain, metabolic syndrome), generic price competition, and patient adherence:
| Formulation | Key Side Effects | Dosing Frequency | Generic Available | Cost per month | Best for |
|---|---|---|---|---|---|
| IR (immediate release) | Sedation, orthostatic hypotension | 2-3x daily | Yes | $10-30 | Acute agitation, bipolar mania |
| XR (extended release) | Sedation (less), weight gain, metabolic | 1x daily | Yes | $20-50 | Maintenance, schizophrenia |
| IR (low dose) | Mild sedation | 1-2x daily | Yes | $10-25 | Off-label sleep, anxiety |
独家观察 (Original Insight): Quetiapine’s side effect profile (sedation, weight gain, metabolic syndrome) limits long-term adherence. Weight gain (2-4 kg average) and increased cholesterol/triglycerides require monitoring. Sedation is beneficial for acute agitation but problematic for daytime dosing. Generic competition has reduced prices by 80-90% since patent expiry. Our analysis recommends: (a) acute agitation/bipolar mania: IR (fast onset), (b) maintenance: XR (once-daily, improved adherence), (c) elderly: low-dose IR (reduced side effects). The market growth (5% CAGR) reflects generic volume expansion.
5. Quetiapine vs. Other Atypical Antipsychotics (2026 Benchmark)
| Parameter | Quetiapine | Risperidone | Olanzapine | Aripiprazole |
|---|---|---|---|---|
| Indications | Schizophrenia, bipolar | Schizophrenia, bipolar | Schizophrenia, bipolar | Schizophrenia, bipolar, depression |
| Sedation | High | Moderate | High | Low |
| Weight gain | Moderate | Moderate | High | Low |
| Metabolic effects | Moderate | Moderate | High | Low |
| EPS risk | Low | Moderate | Low | Very low |
| Generic available | Yes | Yes | Yes | Yes |
| Cost per month (generic) | $10-50 | $10-40 | $15-60 | $20-80 |
| Best for | Sedation-needed, bipolar | General use | Severe symptoms | Metabolic concerns |
6. Regional Market Dynamics
- North America (40% market share): US largest market (Teva, Mylan, Sandoz). High mental health awareness.
- Europe (25% share): UK, Germany, France. Generic adoption.
- Asia-Pacific (30% share, fastest-growing): China (Qilu Pharmaceutical), India (Sun Pharma, Dr. Reddy’s, Lupin, Aurobindo, Hetero). Expanding mental health access.
7. Future Outlook and Strategic Recommendations (2026-2032)
By 2028 expected:
- Once-daily extended-release formulations (improved adherence)
- Lower-cost generics (India, China production)
- Combination therapies (quetiapine + lithium, valproate)
- Personalized dosing (genetic testing for metabolism)
By 2032 potential: long-acting injectable quetiapine (monthly dosing), digital therapeutics (app-based adherence support).
For psychiatrists and patients, quetiapine remains a widely used atypical antipsychotic for schizophrenia and bipolar disorder. 98% purity API dominates branded/generic formulations. Extended-release (XR) improves adherence (once-daily). Key selection factors: (a) formulation (IR vs XR), (b) side effect profile (sedation, weight gain), (c) cost (generic vs branded), (d) patient adherence. As mental health awareness and access expand, the quetiapine market will grow at 5% CAGR through 2032.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
